Good day, everyone, and welcome to the Integra LifeSciences Third Quarter 2017 Financial Results Call. As a reminder, today's call is being recorded. At this time, I would like to turn the conference over to Mike Beaulieu, Director of Investor Relations. Please go ahead.

Thank you, Betina. Good morning and thank you for joining the Integra LifeSciences Third Quarter 2017 Earnings Conference Call. Joining me on the call are Peter Arduini, our President and Chief Executive Officer and Glenn Coleman, our Chief Financial Officer and Corporate Vice President of International. Earlier this morning, we issued a press release announcing our third quarter 2017 financial results. The release and corresponding earnings presentation, which we will reference during the call, are available at integralife.com under Investors, Events and Presentations in the file named Third Quarter 2017 Earnings Call Presentation. Before we begin, I would like to remind you that many of the statements made during this call may be considered forward-looking statements. Factors that could cause actual results to differ materially are discussed in the company's most recent filings with the SEC. Also, the discussions will include certain non-GAAP financial measures. Reconciliations of any non-GAAP financial measures can be found in today's press release, which is in exhibit to Integra's current report on Form 8-K filed today with the SEC. I will now turn the call over to Pete.

Thank you, Mike and good morning, everyone. If you'll turn to slide 4, I'll begin by sharing some takeaways from the third quarter. I'll also provide an update on the Codman integration and our near and long term financial outlooks. Total sales in the third quarter were $279 million, resulting in organic growth of 1.5%. While this was a disappointing result, we managed to deliver significant accomplishments in the quarter, while dealing with adversity in Puerto Rico. We closed the Codman acquisition, the largest transaction in the company's history, which included a multi-product divestiture and an aggressive closing date, which was achieved. We also implemented action plans to address underperforming areas in our business and launched three new products and finally, we managed through three separate major hurricanes, which impacted both sales and manufacturing results in the quarter. We responded by mitigating a large portion of the financial impact. We estimate the storm related disruptions had an impact of roughly $7 million, including loss procedures and shipments that we were not able to get out of Puerto Rico before the close of the quarter. Excluding this impact, total revenues and adjusted EPS for the quarter would have been within the guidance range that we provided in July. Third quarter organic growth, excluding the storm related disruptions, would have been 4.4%, about 1.5 points below our July guidance, mainly due to underperformance in our Dural Repair and SurgiMend product lines. Cash flow from operations was $45 million, exceeding our expectations, largely because of lower spending and improvements in working capital. This performance demonstrates our ability to generate cash flow, which should increase with the addition of the Codman products in our portfolio. Turning to performance in orthopedics and tissue technologies in the quarter, we delivered strong performance in our core regenerative…

Thanks Pete and good morning everyone. Since Pete just covered the overall company of revenue and adjusted EPS for the quarter, I will move right into our segment performance discussions starting on Slide 5, with specialty surgical solutions. Third quarter reported sales grew 3.4% to $165 million with organic sales increasing 2.7%. Tissue ablation sales increased double digits over the prior year driven by strong capital sales of CUSA Clarity. The global launch of CUSA Clarity is going well in the US and abroad. And we expect the momentum of this product launch to continue to drive growth in our tissue ablation franchise. Earlier this month, we attended the CNS Annual Meeting and the European Neurosurgery Society Meeting where CUSA Clarity was a featured product. We continue to receive positive feedback from our global customers base on Clarity's ergonomic design, streamlined operating room set up and enhanced surgical performance which can provide a fibrous tissue removal rate of greater than 50%. Moving to Dural Repair , sales increased about 2% in the quarter which was 2 points lower than our July projections. Although we gave up some price within the quarter, we maintained unit share and have received encouraging feedback about the health economics study we published in August. We anticipate that the economic significance of this study combined with strong clinical data and the expansion of our commercial organization will drive unit growth in our door repair franchise. Sales in Precision Tools & Instruments increased low-single digits compared to the prior-year quarter in line with our expectations. Strong growth in Cranial Stabilization and specialty neuro products were partially offset by lower sales of dental instruments. International sales within the segment increased high-single digits driven by strength in our door repair and tissue ablation franchises in both Asia Pacific and…

Thanks, Glenn. If you will now turn to slide 13, I'll provide an update on our key focus areas for the rest of 2017. While the third quarter was challenging on several fronts, we accomplished a number of milestones that position the company for long term growth. Through the first three quarters of 2017, most of our portfolio is meeting or exceeding our plans, including our core regenerative tissue products, our total ankle and shoulder portfolios and CUSA Clarity. In those areas with no expectations, we have plans in place to improve our performance, including new product introductions, channel enhancements and clinical end marketing programs. We revised our organic growth for the year based partially on under performance of two product families, but largely because of the unprecedented storm activity that occurred in the third quarter. We minimized the impact of our adjusted earnings per share for the year through cost reductions and great work by our operations team, bringing our Puerto Rico facility back online. We closed the Codman acquisition on October 2 and are implementing the integration plan that we meticulously prepared over the last six months and the more we look at Codman, the more encouraged we are in our ability to accelerate growth and profitability in the back half of 2018 and beyond. The Codman deal enables significant channel expansion worldwide and a complimentary product portfolio and pipeline, which positions us to achieve critical scale in many markets around the world. As part of a branding strategy, we're taking advantage of the globally recognized Codman name by rebranding our specialty surgical segment to Codman specialty surgical. This new identity will enable us to utilize the Codman specialty surgical brand in neurosurgery as well as other franchises such as instruments to enhance our global competitive position. Derma…

[Operator Instructions] Our first question today comes from Robbie Marcus of JPMorgan.

Maybe Glenn, a question for you. The 5% organic growth guidance in 2018 is fairly below where the street was modeling, kind of in the 6.5% to 7% organic range. So you bridge 3Q to 4Q, but maybe you could help us bridge what's going to happen between 2017 and 2018 that that will lower it so much versus expectations?

Sure. So when we look at 2018, we're going to be somewhat familiar on the remarks we're going to make, but I would say, when we look at the 5% organic growth, we'd obviously expect orthopedics and tissue business to be growing much faster than that. And our Codman specialty surgical business to be going slower than the overall average and as we look at that, keep in mind, we're going to be integrating the largest acquisition in our company's history in the first half of 2018. We're expecting it to have some disruption on our base business, including our organic business. And so we would expect that to be more limited in terms of organic growth, especially in the first half of the year versus second half of 2018. And if you look at the mix between the two and we expect 5% organic growth as a reasonable assumption right now, given we still have a few months to go to close out 2017.

Robbie, the other thing I would add, this is Pete, just to emphasize Glenn's point here is that fundamentally, every territory in the United States in neurosurgery is going to have some changes done to it. And so we've factored that in and we wanted to make sure that we factored effectively what we think that could be. If we go better than that as Glenn said, we have opportunities for upside beyond that, but we think it's quite prudent just based on the scale of the integration where you have a number two and a number three coming together from a channel standpoint.

All right. Maybe in the third quarter, the things that stood out were Dural Repair , regenerative, SurgiMend was a bit lower, even excluding the hurricane and then CUSA did better than expectations, so maybe can you touch on each of those and what you're seeing in the markets and then how you expect those to play out over the next few quarters.

So, Robbie, do Dural Repair , we were I think probably a little optimistic that we could keep the price and the socket simultaneously from Q3 to Q4. As I mentioned, what was good through the quarter and we saw our market share data, we held on to share and in many cases, in Dural Repair , particularly in the online market and the market, we've gone in many cases without integrated contracts for those products and what we have been doing, this has been part of our strategy, is to have more integrated product strategies in that area. As we thought more pressure in that area, we actually signed up more contracts, really within the last two quarters. And so I would say again in Q3, the biggest part of the price component was signing up to some longer term agreements that I think will give us stability on our market share, on the price side and also have us be in a position that we can focus on growth from this point forward. So I think it was a smart move ultimately to be able to tie the contracts up that resulted in some price. That was the Dural Repair side. On SurgiMend, it's a new business for us that came in from TEI, I'd just kind of broadly say that TEI acquisition, two major product areas, PriMatrix and SurgiMend, PriMatrix is growing at double digits and we continue to see that expanded and we think that SurgiMend is going to be a contributor. What we've been struggling with is getting the right products in the right markets and I would say, in the US, it's been about hernia and having the right regenerative product that can compete price wise with bio absorbable. We think we have the product out, MP product we launched a few months ago, but it takes some time to get that established, get it through fast, get going and that was part of the slower update, probably about half of it was there. The other area is in breast reconstruction outside the United States. There's a change within procedures to do what's called a pre-factorial procedure. You need a different approach and a style of the product. We think we have it. Glen referenced, we just launched it at the end of the quarter and we think that's going to bring back growth. But when we take a look at third quarter, those are really the two negative factors and we think those trends, just because of the time to ramp up is still going to exist into Q4. Glenn, you may want to comment on that before we go to CUSA?

No. I would just say with CUSA, it's a really strong quarter, double digit growth, both in the US and outside the US. So, the global launch is going quite well. I would just temper some expectations over the longer term horizon, next couple of years, we see this franchise growing in the high single digit range, but clearly off to a really strong start. I would also just point out relative to our third quarter results, if you exclude the storm, we actually would have met or hit our revenue guidance, the midpoint of our guidance and actually made above our adjusted EPS. So while we were short on organic growth, even when you remove the storm, we would have been within our guidance ranges for both revenue and probably higher on EPS without the storm impact.

Our next question today comes from Jonathan Demchick of Morgan Stanley.

So, I wanted to follow-up on the hurricane impact actually. I mean you gave a lot of detail and that was really helpful, but when you look at OTT business, it seems like maybe 7 points of growth was perhaps impacted from the hurricane. Can you perhaps give a little more context there as it just seems a lot larger than we would have expected. I mean is a good chunk of this just the private label business, is that the main thing to be thinking about here. And then also heading into the fourth quarter, I was wondering if you're expecting any catch up from that heading into next.

Yeah. John, I'd have Glenn walk through some and then I'll provide some comments. I think you're right. The private label is quite unique and how we actually make it and what we do or don't with stocking, but Glenn why don't you walk through some of those numbers.

Sure. So the hurricane impact for us in the third quarter was about $7 million. Almost all of it was OTT related. And if we look at the components of what happened in the third quarter, $2 million or so was associated with product in private label that did not get off Puerto Rico and the island. So that was product that we were maybe in progress to shipping out but just did not get off in the third quarter. The other $4 million to $5 million is really related to Florida predominantly and the fact we had lost procedures in orthopedic and wound care. So the $7 million impact in the third quarter is almost entirely OTT related. Relative to the fourth quarter, the big impact is really going to be on the private label business. If we look at the $8 million or so of revenue there, probably 2 million of it is related to specialty surgical and some specialty neuro products we make in Puerto Rico, where we have some codes that we're getting well inventory on. But 6 million or so is really private label. And keep in mind we don't keep inventory of private label products, right. So our private label partners obviously has safety stock, but we have no inventory, it's made to order. And so as we gradually ramp up here in Puerto Rico, it's going to take us time to recover some of the manufacturing relative to the private label part of the business.

So just to add some more color to that , I mean private label has been growing nicely as you guys know and we've been focusing in multiple locations, New Jersey as well as Puerto Rico where we have capacity as we move products between those two locations. And Glenn correctly characterized it, we've been in contact with our top private label customers, they have all the adequate inventory in their channels to support their customer needs. So we don't see out of stocks for them or patient issues. But the relative to it, they will be burning down some of their safety stock. So we get an order, we make it, we ship it immediately to them, we don't put it in one of our DCs that's the point. Hence from a recovery standpoint, we believe the majority of all this private label business will recover in the first half of 2018 as we'll be able to make it and replenish their safety stock. Relative to the other products particularly that the Florida scenario in orthopedics, we may unfortunate to pick up some of the cases, but at this point in time we're not counting that those are all going to come back depending on how things get rescheduled, did patients move onto delay the procedure all those kind of things. So quite confident in private label and counting really much of the Florida impact to come back. Q And just one quick follow up on I guess expectations for Codman accretion into '18. It looks like the $0.22 number was moved to $0.25, but I guess now we're also seeing a channel investments part being broken out. I guess my stance on prior guidance was that accretion was already digging in some amount of the build out needed. Is it possible to provide a little bit of context there.

So just to be clear, the channel investment we're talking about isn't to do with specialty surgical is that we're using some of the accretion to actually really address a chronic issue we've had for the last few years, which was to be able to expand our OTT channel and address some of the issues we've had. It's no secret that we've struggled in our lower extremities franchise ex-ankle to be able to get to the kind of growth that we think we need. This is a move to fund our channel to be able to expand it based on really positive experience we've had in pilot so to speak on our ankle and our shoulder. So that's part of it. The other side of it than is our in-patient products, which we continue to do quite well on. Our whole Integra line, our PriMatrix line. I would tell you I believe we're still channel constrained on our ability to expand. And so the $0.07 that Glenn reference is about applying that towards the orthopedics and the tissue business to expand it to drive future growth.

Our next question comes from Matt O'Brien from Piper Jaffray. Please go ahead.

Hi, good morning everyone, this is J.P. on for Matt, thanks for taking the questions. To go back to Dural side, I mean when we left Q2 it seemed that a competitor had more inventory, was competing on price and it was going to be more of a temporary type scenario. But now it sounds like you're signing longer term contracts. So was it more that you found that the competitor was - that competition on price was here to stay, so that kind of forced you into doing some longer term contracts or so what's changed I guess.

Well, I just think again, it's a very completive healthcare market, no matter if it's Dural Repair or if it's other types of devices. If you're having a discussion with a customer, two products seem relatively equivalent, we've done some I think very good work to show that they're not in some of the studies that we have out there. But we've made some decision to stay that if we have an opportunity to do contracting, give up a little bit of price still very profitable product for the company and reduce that volatility going forward it just makes sense. And so that's what we did within the quarter and that resulted in lower growth rate than we initially projected. But again I think to the future, it's going to provide more stability, consistency in that number.

And then can you just help me reconcile the additional OTT spend, why won't that for 2018, why won't that just be counted in kind your organic EPS growth. And then just reconciling that with - normally when you make a good investment layoff, a high investment like that you should expect correlation in growth, but you lowered longer term growth targets. Can you help kind of fish those two out, is it more of your investment in '18, you're going to see acceleration in '19 and '20 on the OTT side, or how should we think about that.

I'll talk about the broader picture and then maybe Glenn, you can jump at how we layout the accretion and using some of that spend. First of all when we think about our original six to eight to five to seven that primarily is aligned with reflecting the addition of Derma Sciences, the addition of Codman and what that does to the broader mix of the growth. It is about a point shift that brings us down from an overall gross standpoint. Clearly within '18, we are adjusting and recommending a 5% for modeling purposes because in the first half of the year, we're going to be integrating all of the channel, again, as we close Codman for the fourth quarter, we're still running the channel separately, which is a higher SG&A burden and then we'll be doing some integration in the first quarter and second quarters of 2018 as well as expanding the OTT channel. So as I mentioned in the second half of '18, we expect the growth to start to pick up for sure, we up that rate. And as we go into '19 and '20, we think it definitely sets us up for accelerating growth, most likely into the higher end of that range. But we felt it was prudent just based on the major change with adding Codman into the portfolio that we adjust, you know, how we see our long-term guidance range in the five to seven points. So Glenn, if you want to add any other comments.

Yeah J.P., the only other thing I would say is, relative to the $0.07, this is incremental above and beyond the normal investments we would make within OTT. So it's not just year-over-year up seven, it's incrementally about what we would normally have as an increase for orthopedics and tissue. And to your point, we would expect that growth to really start to accelerate into 2019. Keep in mind for 2018, we still expect to see growth like we put up in a past in the high-single low-double digit range for this part of our business. But if you think about these investments we're going to make in areas where we struggled recently like lower extremities outside of ankle and the opportunities we see with in-patient skin and continuing to grow that even faster, we think it's necessary to make these types of investments to really position ourselves for a long-term growth beyond 2018. But the $0.07 is clearly incremental to the normal investments we would make within this part of our business.

[indiscernible] at our investor conference in December we'll plan on giving some more color around how we think about some of the channel investments in both of these businesses.

Our next question today comes from Raj Denhoy of Jefferies.

What if I could come back again, I know it's been hit on a few times, but this change in your outlook for the longer term growth of the business. If I'm hearing you, it sounds like it's primarily in the orthopedic tissue business, the OTT business and also obviously that's the requirement now for the investment next year to support the growth there. So I'm curious if you could maybe give us a bit more in terms of what you're seeing in that business. Is it just that it's harder to get traction, is it turning more to be more competitive than you thought and why this sort of reduced outlook in that business in particular.

So, Raj, it's not at all to do with OTT. It's really to do with the 300 million of revenue coming in from Codman that's growing in low single digits that we're going to integrate into our neuro business and then move those into mid-single digit growers. It takes time to do that. We expect OTT to be putting up low double digit numbers, high single digit numbers within that area and this investment really assures that we can, because it's supplementing areas that have not contributed at the level we think they could at the last few years, in patient would is still growing very well, in many cases, high single, low double We think to even do better with more resources and in the case of lower, where we've actually been down or clearly not to market share to be able to get our fair share of that market. So it actually is not OTT, it's the SSS effect and then we're bolstering so to speak OTT to be able to outperform in areas that we have not in the past.

Right. So I guess, so it really is, as you look at that longer term - long term growth rate, it's just the mix of Codman and other, it's the Codman revenue coming in. That's how we should think about that.

That's clearly the change of why we're representing 6% to 8% to 5% to 7% is the percentage of revenue now that we have that's growing at low single digits and we believe over the long run, we'll be able to increase that, but we think the 5% to 7% range is more realistic about how you should think it for modeling over the next few years.

And then maybe just then over the short term, right, on the orthopedic and tissue technologies business, you didn't give us any updates on OmniGraft, how that's doing, I think you may have just alluded to it with what you're saying on the inpatient would side, but any updates on OmniGraft and the adoption there? And then on the SurgiMend products, what is the issue there? Is it again competitive or what is holding the adoption of that product?

Yes. So, Raj, look, on the outpatient would care side, we continue to do well, which is a combination of OmniGraft and also PriMatrix small sizes as well as the Derma Sciences products that we brought in and if you remember, just a few months ago, we integrated the channels. We have a channel [indiscernible] which is still small versus many of our competitors, but we think it's adequate right now and we're on track to over perform against what we had communicated earlier, specifically about OmniGraft, since we've adjusted our expectations here in the second quarter about how we see it to grow, it's on track to the level of growth. We are picking up new users. We're actually being able to build that out, but more methodically as we talked about. I would tell you and we'll talk a little bit more about this in December, our reimbursement strategies are coming along, which is going to be a really important part for OmniGraft to continue to grow, but now that we have this three by three strategy where we have an amniotic and we have two other technologies, PriMatrix and OmniGraft, all three of them are contributing right now to our overall growth. And relative to SurgiMend, on the earnings side, it definitely is competitive, it's the bioabsorbables in the United States and again with our macroporous product that we just recently launched, there's a lot of interest in it because we can hit the price point, but it doesn't have some of the side effects or some of the related issues that you have with synthetics or bioabsorbables. And so we think that's going to take a little bit of time, but in '18, we're going to see some positive growth coming out in that market and in Europe, for the breast market, it's less competitive and it's more of procedure change that we think we're actually on the front end of. And so we're going to start seeing some pickups in this meshed product that is designed to actually help in this new procedure, which is a pre-factorial procedure related to breast reconstruction.

Our next question comes from Matt Taylor of Barclays.

Hi. This is Ian Mahmud on for Matt. I just had one question for you. I wanted to focus on Derma Sciences, specifically for a bit. You noted that revenue outperformed your expectations during the quarter. I was just hoping you could maybe dig into that a little bit and provide some more detail on what drove that outperformance and maybe explain kind of how this is going to factor in as a driver going forward into 4Q and 2018?

I don't think I'll crack at this one. So for Derma Sciences, in the quarter, did about $24 million of revenue which actually was a couple of million dollars better than we thought. Keeping in mind that in mid-July timeframe, we had the entire outpatient team, out of the field training the combined portfolio. So the team did quite well in terms of driving both year over year growth on a pro forma basis as well as sequential growth, especially when you consider the fact they were out in the field for a week and really what we're seeing is growth in the MEDIHONEY product as well as the amniotic tissue product and those products are key drivers for us as we look out at Q4 as well as into 2018. When we look at the overall Derma portfolio, I would say I'd expect it to grow pretty much in line with the overall corporate average. So whatever the organic growth rates are on a 5% to 7% range is where we see Derma growing over the long term, as we cross sell their products with this channel now that's got 80 reps and hopefully, we'll see that channel go up overtime in 2018 and 2019. The traditional wound care part of the business is a slower growing part of the business and obviously that is a bit of a drag on growth, but clearly we're looking at that as an area that we could actually do better in as well, but I would say the key growth area is really advanced wound care and MEDIHONEY, along with the total contact cast foot, which is doing quite well as well.

We will now take a question from Jayson Bedford of Raymond James.

Just a few questions. So I'd like to talk about end market growth and obviously I don't want to pre-empt the investor event, but I guess the way we're thinking of your market kind of four percent-ish, 4%, 5% neurosurgery growth, regenerative medicine kind of 8% to 10%, extremity kind of 8% to 10%, which I think supports maybe a 5% to 7% end market growth rate, can you just one comment, if those numbers are in the ballpark?

I think, what you quoted you, yeah, that's definitely in the ballpark and to your point, I mean, these are some of the areas that we'll give more detail on in December.

Okay. The 5% organic growth expectation for next year, just to be clear, does that reflect some Puerto Rico spillover?

Yet. It assumes $10 million coming into 2018 for Puerto Rico. Positive. So it's actually Puerto Rico recovery that we pick some in that point in time, which is just the private label shipments that we referenced.

Okay. And then lastly, there was no change to the gross margin target. Given the Puerto Rico disruption, what's allowing you to hold gross margin in the fourth quarter here and then should we expect some kind of spillover softness in the first half of '18?

So, we ended up doing, I would say, a little bit better on gross margins in the third quarter. When we look at the fourth quarter, we're basically saying, it should be pretty much in line with the third quarter, which basically assumes some improvement in our base business offset by some dilution from Codman, right. The Codman has lower gross margins that our base business. We think the effects for Puerto Rico will be minimal on gross margins and we have called that about $1 million impact in our special charges in the third quarter associated with that. As we look out to next year, I would just say my expectation without giving guidance here is, we'd be down slightly on gross margins, just because of the Codman dilution. So having Codman in for the full year we'll be somewhat dilutive to our gross margins and that would be offset somewhat by improvements in our base business. But looking at 2018, I would just say at a high level, probably slightly lower gross margins given the Codman dilution. Having said that we do expect pretty meaningful EBITDA margin expansion because Codman is accretive to EBITDA margins. As we look at 2018 that's kind of at a high level how we framed it out, our EPS guidance.

What I would add is that, some of this is going to be terminated on well our launches that we are coming out with have continued to grow. The great part about our base businesses, most of our recent launches in our core growth processes are all accretive to our gross margin. you think of our ankle being accretive by five to six points, shoulder same case, Clarity even more than that and also remains in a low tax jurisdiction in Ireland. Our inpatient tissue business, the PriMatrix business that's growing quite well, and as SurgiMend turned around that will be a very high contributor from a gross margin standpoint. So again that's why a lot of focus on those areas. But to Glenn's point with as much integration as we have going on in the first half of '18 for the whole company, we're are tempering what we actually think our performance can be in that first half.

[Operator Instructions] We will now take a question from Steven Lichtman of Oppenheimer & Co. Please go ahead.

Just the first question relative to international, can you give us your latest thoughts on the infrastructure that Codman brings and how that could potentially possibly impact the core Integra international franchise. I know in Japan you've highlighted that. And how do you factor that into your thinking on growth in '18 and in the long term.

It's a good question, I'll comment on the infrastructure first as it relates to kind of the core functions to support the business, meaning customer service, distribution logistics, warehousing, IT. We get very little from Codman because it's carved out from J&J, right. So we have to set all of that infrastructure up ourselves as it relates to running the business, taking orders, customer service, all those areas. So that's all work we have to do over the next couple of years. As you go through that set up of the infrastructure, we have transition services agreement in place with J&J to help ensure a smooth transition. When I think about the sales infrastructure, this is the really exciting part of this merger. And I look at the amount of resources we're going to get in Europe as an example; we'll increase our footprint by 50%. But really when I look at Asia Pacific, we more than doubled the resources there. And if I specifically maybe look at Japan as one specific market, you look at our resources today in Japan is about 11 people, Codman brings in more than 60. Now we can take this combined organization of 70 plus commercial reps directly in Japan, a very large market and will be launching meaningful new product launches in the end of 2018. So DuraGen, CUSA Clarity and we can put those new product launches through this very large channel and go direct. That's really where the infrastructure is going to benefit us on the commercial side as an example. But outside of the selling and commercial resources area, Steve, we get very little infrastructure in the other areas that I mentioned.

Steve, the only thing I would add, I think Glenn hit it on, just I mean again, this is why we're so excited about Codman, just in neurosurgery 40% to 50% more reps worldwide now all selling Dural Repair , now all selling CUSA, now all selling Mayfield, now all selling [indiscernible]. So big impact potential once integrated and what that means for growth over the next three years. And then for OTT, there will be markets such as Japan and really in Western Europe where we couldn't contemplate taking some of our legacy products in our issue side and going direct or really being able to support them because we didn't have the right structure, we'd outrun our supply lines and that will change because of the structure we're putting in place with Codman.

Steve, just a last point on infrastructure. So once we actually build out the infrastructure needed to support this business, keep in mind we can leverage that infrastructure across the other part of business in orthopedics and tissue. So that same infrastructure can be leveraged down the road and we see a lot of benefits in that as well.

And then just on Dural Repair , you had talked about in the second quarter that perhaps contracting would be one way to kind of fight back on some of the pricing pressure and you executed on some of that. As part of these new contracts, are the more volume tied with that over time or is really the benefit through the line of sight visibility that you get.

Ultimately, it's more volume, Steve. And the way some of these work is, they're multi-product. And if they're multi-product, they're about volumes discount based on an aggregate buy and sell. So if you only bought 70% of these, you'll only get a certain price, if you bought 95%, you get more. That's pretty typical. That's the majority of them. In some cases we haven't had those included in the contracts, which allowed us to have a little bit more flexibility on how we may think about price for skews. And so, in this case we've opted to bring more of those in. And again it takes price away in the near term and actually gives you more consistency and actually even some potential price over the long run if you're locked in. So that's how we looked at it. And again, we obviously would have liked to have been able to kind of get the number, but I think being able to actually take the hit now, we have a lot - some of these contracts in was the smart move for us to do.

As there are no…

Operator I think…

Please go ahead

Thank you. So thanks operator and everyone thanks for all your time and attention. I know it's been a busy week and month. And we hope we will see many of you in December in New York City. We'll be putting out some more details on that, but that will be December 11th in New York. And we plan on giving more details, particularly on some of our strategic overviews of both of the businesses, some more insights into these product synergies and geographical opportunities as well as how we see some of the outer years taking shape strategically for us. So again thanks for your time and that concludes our call. Thank you very much.

Thank you.

That will conclude today's conference call. Thank you for your participation. Ladies and gentlemen you may now disconnect.